重组带状疱疹疫苗在50岁及以上成人中的安全性:IIIB期开放标签研究
本研究为IIIB期、非随机、多国、开放标签研究,向ZOE-50和ZOE-70安慰剂受者提供重组带状疱疹疫苗(RZV)。在8687名接种者中,97.8%完成2剂程序;30天内59.6%报告至少1项非征集不良事件(AE),50.9%为接种相关;最常见为注射部位反应、发热和头痛。研究期间8.4%报告严重AE,0.7%报告潜在免疫介导疾病,各2例判定为接种相关;0.3%报告疑似带状疱疹发作。AE性质与发生率与母研究一致。
要点
- RZV在50岁及以上成人中安全性良好,AE谱与母研究一致。
- 30天内非征集AE发生率59.6%,多为注射部位反应、发热和头痛。
- 严重AE和潜在免疫介导疾病发生率低,接种相关者极少。
核心结论
- RZV在既往ZOE-50和ZOE-70安慰剂受者中安全性特征与母研究一致。
研究设计与样本
- IIIB期、非随机、多国、开放标签研究,向ZOE-50和ZOE-70安慰剂受者提供RZV。
- 14550名合格参与者中8687人接种RZV,97.8%完成2剂程序,接种后随访12个月。
主要发现
- 接种后30天内,5175人(59.6%)报告至少1项非征集AE,4422人(50.9%)为接种相关。
- 最常见AE为注射部位反应、发热和头痛。
- 研究期间734人(8.4%)报告至少1项严重AE,62人(0.7%)报告至少1项潜在免疫介导疾病,各2例判定为接种相关。
- 30人(0.3%)报告疑似带状疱疹发作。
临床怎么用
- 对于50岁及以上成人,包括既往带状疱疹疫苗安慰剂受者,RZV接种的安全性可预期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efficacy of the adjuvanted recombinant zoster vaccine (RZV) against herpes zoster (HZ) was demonstrated in pivotal trials ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229). This study was designed to offer RZV to placebo recipients of these parent studies. METHODS: Vaccine safety and suspected HZ episode occurrence were assessed for 12 months following vaccination. RESULTS: Of the 14,550 eligible participants, 8687 received RZV and 97.8% completed the 2-dose schedule. During the 30-day post-vaccination period, 5175 (59.6%) participants experienced ≥ 1 unsolicited adverse event (AE), 4422 (50.9%) were vaccination-related. The most common AEs were injection-site reactions, pyrexia, and headache. During the study, 734 (8.4%) participants reported ≥ 1 serious AE (SAE) and 62 (0.7%) reported ≥ 1 potential immune-mediated disease (pIMD); 2 of each were assessed as vaccination-related. Suspected HZ episodes were reported by 30 participants (0.3%). CONCLUSIONS: Nature and incidence of AEs, SAEs, and pIMDs were as expected and in line with the parent studies.
引用
- Ocran-Appiah J, Boutry C, Hervé C, et al. Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients. Vaccine. 2020. PMID: 33277059. doi:10.1016/j.vaccine.2020.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。